Advanced search
Publication Cover
Expert Review of Pharmacoeconomics & Outcomes Research Volume 15, 2015 - Issue 5
Submit an article Journal homepage
239
Views
8
CrossRef citations to date
0
Altmetric
Research Report

What impact does ‘conventional’ economic evaluation have on patient access to new orphan medicines? A comparative study of their reimbursement in Australia (2005–2012)

Michael WonderWonder Drug Consulting, Cronulla, New South Wales, AustraliaCorrespondence[email protected]
&
Geoffrey ChinNovartis Pharmaceuticals Australia, North Ryde, NSW, Australia
Pages 843-850 | Published online: 04 May 2015

Citations (8)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Kentaro Kogushi, Toshio Ogawa & Shunya Ikeda. (2020) An impact analysis of the implementation of health technology assessment for new treatment of orphan diseases in Japan. Expert Review of Pharmacoeconomics & Outcomes Research 20:5, pages 455-471.
Read now

Articles from other publishers (7)

Mohammad M. Haque, Mutsa Gumbie, Megan Gu & Gnanadarsha Dissanayake. (2022) Factors associated with Pharmaceutical Benefits Advisory Committee decisions for listing medicines for diabetes and its associated complications. Australian Health Review 47:2, pages 139-147.
Crossref
Yu-Jun Huang, Wan-Yu Chao, Chi-Chuan Wang & Lin-Chau Chang. (2022) Orphan drug development: The impact of regulatory and reimbursement frameworks. Drug Discovery Today 27:6, pages 1724-1732.
Crossref
Olga A. Belousova, Aard J. Groen & Aniek M. Ouendag. (2020) Opportunities and barriers for innovation and entrepreneurship in orphan drug development. Technological Forecasting and Social Change 161, pages 120333.
Crossref
Yen Hoang Le Phan, Richard De Abreu Lourenco, Marion Haas & Naomi van der Linden. (2018) Key considerations in reimbursement decision-making for multiple sclerosis drugs in Australia. Multiple Sclerosis and Related Disorders 25, pages 144-149.
Crossref
Agnes Isabelle Vitry & Russell Shute. 2018. Equitable Access to High-Cost Pharmaceuticals. Equitable Access to High-Cost Pharmaceuticals 165 181 .
Irina Degtiar. (2017) A review of international coverage and pricing strategies for personalized medicine and orphan drugs. Health Policy 121:12, pages 1240-1248.
Crossref
Michael Wonder. (2016) Registration and Reimbursement of New Cancer Medicines in Australia. Value in Health Regional Issues 9, pages 63-64.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.